The Global Autoimmune Monoclonal Antibodies Market report published by Market Data Forecast provides a detailed account of the Market Trends via Customized Research presented as Strategic Analyses, Company Profiles, and Competitive Landscape etc. According to the report, the Global Autoimmune Monoclonal Antibodies Market is projected to reach USD 29393.08 million by 2023 from USD 20153.28 million in 2018 with a CAGR of 7.84%. The market is segmented based on source, application, and end user. Based on source, the market is further sub-segmented as Murine, Chimeric, Humanized, & Human, based on application, the market is further segmented as Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Transplant Rejection/Graft Versus Host Disease, & Others, and based on end user the market is segmented as Hospitals/Clinics, Research Institutes, & Diagnostic Laboratories. Further the market is also geographically segmented into North America, Europe, Asia-Pacific, Latin America, and Middle-East & Africa.
Growing research & development to stimulate the development of monoclonal antibodies rising number of patients with autoimmune diseases, and increasing public & private organizations involvement to support advanced therapeutics development are driving the growth of global autoimmune monoclonal antibodies market. In addition, rising demand for antibody based therapeutics, increasing adoption of advanced healthcare therapeutics, and growing number of lifestyle associated disorders are further promoting the growth of global autoimmune monoclonal antibodies. However, presence of stringent regulatory pathways, lack of advanced research facilities & underdeveloped healthcare infrastructure in certain developing regions, and limited accessibility of monoclonal antibodies therapeutics due to high cost are restraining the growth of autoimmune monoclonal antibodies.
North America accounted for the largest market share of 45.0% of global autoimmune monoclonal antibodies market and growing at the highest CAGR of 8.47% owing to growing number of patients with autoimmune diseases, increasing research and development to promote the development of monoclonal antibodies, presence of large number of biotechnology companies, and rising demand for effective therapeutics. In addition, increasing innovations in monoclonal antibodies research, rising number of product launches, and growing number of collaborations & agreements to promote autoimmune therapies using monoclonal antibodies are further supporting the growth of autoimmune monoclonal antibodies market in North America.
The key players in global autoimmune monoclonal antibodies market include, GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Innovent Biologics, Inc. (China), Takeda Pharmaceutical Company Ltd. (Japan), Amgen Inc. (U.S.), Biogen Inc.(U.S.), and UCB Company (Belgium).for more information visit “http://www.marketdataforecast.com/market-reports/global-autoimmune-monoclonal-antibodies-1170/” and for forther reports in Therapeutics category visit “http://www.marketdataforecast.com/research-reports/healthcare/therapeutics-11/”